Ticker: LEXX

Lexaria Bioscience Corp. (NASDAQ: LEXX) has recently released its quarterly report for the period ending May 31, 2025, revealing a mix of financial trends that reflect the company's ongoing activities and challenges. Financial Highlights: Revenue: $531,923 (up from $380,278 in 2024). Net loss: $...

Company Overview Lexaria Bioscience Corp. (NASDAQ: LEXX) focuses on enhancing the bioavailability of active pharmaceutical ingredients (APIs) through its proprietary DehydraTECH technology. The company aims to improve the absorption and reduce side effects of various drugs, particularly for treat...